Abbott confirmed that its acquisition of Exact Sciences is on track to close on March 23, 2026, with the cancer diagnostics company set to become a wholly owned subsidiary upon completion of the transaction. The deal represents a major strategic expansion for Abbott into the cancer screening and precision oncology diagnostics market.
The acquisition brings together Abbott’s global healthcare infrastructure with Exact Sciences’ portfolio of cancer detection and monitoring tests, including Cologuard for colorectal cancer screening and Oncotype DX for breast cancer treatment guidance. Abbott, listed on the NYSE under the ticker ABT, currently operates across diagnostics, medical devices, nutritionals, and branded generic medicines in more than 160 countries.